Publications by authors named "R A Klimova"

It is estimated that nearly all individuals have been infected with herpesviruses, with herpes simplex virus type 1 (HSV-1) representing the most prevalent virus. In most cases, HSV-1 causes non-life-threatening skin damage in adults. However, in patients with compromised immune systems, it can cause serious diseases, including death.

View Article and Find Full Text PDF

Introduction: SARS-CoV-2 infection causes immune disorders that create conditions for the reactivation of human herpesviruses (HHVs). However, the estimates of the HHVs effect on the course and outcome of COVID-19 are ambiguous. Аim - to study the possible relationship between the HHV reactivation and the adverse outcome of COVID-19.

View Article and Find Full Text PDF

Hepatitis C virus (HCV) is one of the basic culprits behind chronic liver disease, which may result in cirrhosis and hepatocarcinoma. In spite of the extensive research conducted, a vaccine against HCV has not been yet created. We have obtained human mesenchymal stem cells (hMSCs) and used them for expressing the HCV NS5A protein as a model vaccination platform.

View Article and Find Full Text PDF
Article Synopsis
  • Almost everyone gets infected with herpes viruses, like HSV-1, which can stay in a dormant state resistant to current antiviral treatments.
  • Reactivation of these viruses can occur under certain conditions, and drug-resistant strains are becoming more common, highlighting the need for new treatment methods.
  • The study explores CRISPR/Cas systems as a potential therapy, demonstrating that engineered plasmids can effectively suppress HSV-1 infection in cell cultures for extended periods.
View Article and Find Full Text PDF

Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) infect almost all organs and tissues, cause genital herpes-the most common sexually transmitted disease-disorders of the central nervous system (CNS), and lead to severe complications in children. Despite the available drugs, the incidence of HSV-1/2 continues to rise. None of the prophylactic vaccine candidates have shown a protective effect in trials nor approval for use in clinical practice.

View Article and Find Full Text PDF